Results 121 to 130 of about 222,331 (336)

IGFBP5 Restores Endometrial Receptivity and Rescues Implantation Failure in Polycystic Ovary Syndrome

open access: yesAdvanced Science, EarlyView.
Impaired endometrial receptivity contributes to the poor pregnancy outcomes in women with PCOS. The authors found that decreased endometrial IL‐22 levels and disrupted STAT3‐IGFBP5 signaling pathway contributed to impaired endometrial receptivity. Supplementation with IL‐22 or IGFBP5 exerts a protective effect on implantation failure in PCOS‐like mice,
Baoying Liao   +13 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

open access: yesAdvanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu   +7 more
wiley   +1 more source

Prognostic significance of KI-67 in renal cell carcinoma: correlation with clinicopathological parameters and survival outcomes

open access: yesHuman Pathology Reports
Background: Renal cell carcinoma (RCC) is a heterogeneous malignancy with variable clinical behaviour. Ki-67, a nuclear antigen associated with cellular proliferation, has been investigated for its prognostic relevance in RCC.
Krutika Kantilal Raskar   +2 more
doaj   +1 more source

Ki-67 Antibody Immunostaining in Benign and Malignant Human Prostatic Disease

open access: yesThe International Journal of Biological Markers, 1992
Indices of mitotic potential may improve prognostic discrimination in patients with malignant disease. Ki-67 is a monoclonal antibody directed against an unknown proliferation antigen which has been shown to be a measure of mitotic potential.
S.N. Lloyd, I.L. Brown, R.E. Leake
doaj   +1 more source

Integrating Spatial Proteogenomics in Cancer Research

open access: yesAdvanced Science, EarlyView.
Xx xx. ABSTRACT Background: Spatial proteogenomics marks a paradigm shift in oncology by integrating molecular analysis with spatial information from both spatial proteomics and other data modalities (e.g., spatial transcriptomics), thereby unveiling tumor heterogeneity and dynamic changes in the microenvironment.
Yida Wang   +13 more
wiley   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

open access: yesAdvanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li   +10 more
wiley   +1 more source

A statistical mechanics approach to autopoietic immune networks

open access: yes, 2010
The aim of this work is to try to bridge over theoretical immunology and disordered statistical mechanics. Our long term hope is to contribute to the development of a quantitative theoretical immunology from which practical applications may stem.
Abbas A K   +24 more
core   +1 more source

Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Biomimetic MOF‐based drug delivery nanoplatforms synthesized using liposomes or cell membranes as camouflage for multiple cancer therapeutics. ABSTRACT The integration of metal‐organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine.
Qilu Wu   +6 more
wiley   +1 more source

Promoter Hypermethylation‐Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5‐Mediated Wnt/β‐Catenin Pathway Activation

open access: yesAdvanced Science, EarlyView.
This study identifies FXYD1 as an epigenetically silenced tumor suppressor in breast cancer. DNA methylation turns off the gene FXYD1 in breast cancer, and low levels predict worse outcomes. Restoring FXYD1 limits breast cancer cells proliferation and metastasis. In the nucleus, FXYD1 recruits the E3 ligase MAEA to K63‐ubiquitinate DDX5 for proteasomal
Ping Wen   +11 more
wiley   +1 more source

KI-67 IMMUNOHISTOHEMICAL EXPRESSION IN PROSTATIC LESIONS

open access: yesThe Iraqi Journal of Medical Sciences, 2017
Background: The cell proliferation marker, ki-67, is a nuclear and nucleolar protein, which can be detected during all active phases of the cell cycle (G1, S, G2, and mitosis), but absent from cell resting phases.
Inas A. Rasheed   +2 more
doaj   +6 more sources

Home - About - Disclaimer - Privacy